From the FDA Drug Label
The FDA drug label does not answer the question.
From the Research
Bacitracin for intravenous (IV) use is no longer commonly administered in Israel due to its significant nephrotoxicity and other adverse effects, and its use has been largely discontinued in favor of safer alternative antibiotics. The IV formulation was previously marketed under brand names such as Bacticin and Baci-IM, but it is now primarily available as a topical preparation for skin infections or as an ophthalmic ointment.
Key Points
- Bacitracin's mechanism of action involves inhibiting bacterial cell wall synthesis, but its narrow therapeutic window when given systemically led to its replacement by safer antibiotics 1.
- The use of bacitracin has been associated with significant nephrotoxicity, which can lead to acute kidney injury (AKI) and other renal complications 2, 3.
- In Israel, as in most countries, modern healthcare providers typically use safer alternative antibiotics with better safety profiles and efficacy for systemic infections that might have previously been treated with bacitracin.
- If you're seeking treatment for an infection in Israel, consult with a healthcare provider who can recommend appropriate alternatives based on the specific infection and antibiotic sensitivity testing.
Recommendations
- Avoid using intravenous bacitracin due to its significant nephrotoxicity and other adverse effects.
- Use safer alternative antibiotics with better safety profiles and efficacy for systemic infections.
- Consult with a healthcare provider to determine the best course of treatment for a specific infection.
Evidence
The evidence suggests that bacitracin is no longer a viable option for intravenous use due to its significant nephrotoxicity and other adverse effects 4, 2, 3, 1, 5. Instead, safer alternative antibiotics should be used to treat systemic infections.